贝达药业：盐酸恩沙替尼胶囊术后辅助治疗适应症药品注册申请获受理

Core Viewpoint - The announcement indicates that the company has received acceptance from the National Medical Products Administration (NMPA) for its application of a new drug, which is a significant step towards potential market entry for the treatment of specific lung cancer patients [1] Group 1: Company Information - The company, Betta Pharmaceuticals (stock code: 300558), has announced that it received an acceptance notice from the NMPA for its application of the drug, Enasidenib Hydrochloride Capsules (brand name: Baimena®) [1] - The drug is intended for postoperative adjuvant therapy in patients with ALK-positive non-small cell lung cancer (NSCLC) at stages IB to IIIB, who have previously undergone surgical resection [1] - The decision for patients to receive or not receive adjuvant chemotherapy will be made by their physicians [1] Group 2: Industry Context - The acceptance of the drug application by NMPA represents a crucial regulatory milestone in the pharmaceutical industry, particularly for oncology treatments [1] - The focus on ALK-positive NSCLC highlights the ongoing advancements and targeted therapies being developed within the cancer treatment sector [1]